Bionyra Pharma
Immunology & Inflammation Therapeutics · Biologics & Biosimilars
Overview
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation biologics for severe immune-mediated inflammatory diseases. Bionyra’s.
Funding and backers
Backers
2
Jeito Capital, Sofinnova Partners
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 23
Increased its share capital $96k · BODACC
May 4
Increased its share capital $67k · BODACC
Nov 5, 2025
Increased its share capital $16k · BODACC
Registers and programsofficial lists and records that name the company
| Legal entity | Bionyra Pharma SAS | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Quell Therapeutics is a clinical-stage company, fuelled by curiosity and discovery, on a mission to make life better for those battling…
EnteroBiotix is a clinical-stage biopharmaceutical company developing best-in-class full-spectrum microbial therapeutics.
Elevara Medicines is a clinical-stage biotech. ELV001 targets fibroblast-like synoviocytes and synergizes with DMARDs to achieve clinical…
We are using a precision approach to develop therapies designed to transform the lives of patients with immune-mediated diseases.
A biotech company developing better medicines for patients with autoimmune and inflammatory diseases. Leveraging powerful insights into the…
Mirador Therapeutics is a clinical-stage precision medicine company developing therapies for immune-mediated inflammatory and fibrotic…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Jeito CapitalVia a fund
Sofinnova PartnersVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
First healthy volunteers dosed in Bionyra's Phase I BYN-001 study
The study will assess the tolerability, safety, pharmacodynamics and pharmacokinetics in healthy individuals.
Read more
Report
Bionyra Pharma Announces First Healthy Volunteers Dosed in Phase 1 Study of BYN-001, a Long-Acting IL-25 Antibody for Atopic Dermatitis
BYN-001 targets IL-25, an emerging upstream regulator of Type 2 inflammation implicated in atopic dermatitis, and leverages half-life extension technology Bionyra is building a broad IL-25 franchise, including a preclinical IL-25IL-13 multispecific antibo
Read more
Report
Bionyra Pharma Announces First Healthy Volunteers Dosed in Phase 1 Study of BYN-001, a Long-Acting IL-25 Antibody for Atopic Dermatitis
PARIS & BOSTON, September 10, 2026--Bionyra Pharma Announces First Healthy Volunteers Dosed in Phase 1 Study of BYN-001, a Long-Acting IL-25 Antibody for Atopic Dermatitis
Read more
Report
Bionyra Pharma Announces First Healthy Volunteers Dosed in Phase 1 Study of BYN-001, a Long-Acting IL-25 Antibody for Atopic Dermatitis
Read more
Report
TrueLab Biopharmaceutical Announces License Agreement with Bionyra Pharma for Two Next-Generation Monoclonal and Bispecific Antibodies for Immune-Mediated Inflammatory Diseases Valued up to $985 Million
TrueLab Biopharmaceutical, an immunology-driven innovator leveraging a proprietary, AI-powered R&D platform to develop transformative therapies for immune-mediated inflammatory diseases, today announced that it has entered into an exclusive license agreem
Read more
Report
TrueLab Biopharmaceutical Co., Ltd.: TrueLab Biopharmaceutical Announces License Agreement with Bionyra Pharma for Two Next-Generation Monoclonal and Bispecific Antibodies for Immune-Mediated Inflammatory Diseases Valued up to $985 Million
NINGBO, China, June 22, 2026 /PRNewswire/ -- TrueLab Biopharmaceutical, an immunology-driven innovator leveraging a proprietary, AI-powered R&D platform to develop transformative therapies for
Read more
Report
Bionyra Pharma Launches with $165 million Oversubscribed Series A to Advance Clinical Stage Pipeline of Next Generation Biologics for Immune-Mediated Inflammatory Diseases
PARIS and BOSTON - June 22, 2026 - Bionyra Pharma, a clinical-stage biopharmaceutical company developing next-generation biologics for immune-mediated
Read more
Report
